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To the Editor,  
Urine drug testing is widely applied in health care as well as forensic situations or even at the 
workplace. The simplicity of use and fast availability of results have increased the application 
of immunoassays to urine drug testing. However, these immunoassays are not impeccable and 
carry the risk of providing false-positive and false-negative results (1). Therefore, the results 
of immunoassays are considered only as presumptive until confirmed by a specific method 
like GC-MS or LC-MS. The effective screening assay should be characterized by high 
specificity for the target compound and sufficient sensitivity to detect drug or its metabolites 
at relevant concentrations.  
Lysergic acid diethylamide (LSD) is one of the most potent hallucinogens known to man. 
However, its detection in urine is challenging due the very low doses ingested (moderate dose 
of 75-150 μg) and the rapid and extensive metabolism with the elimination half-life of 3-4 
hours (2). 
Several immunoassays for the LSD urine screening are commercially available for a variety 
of autoanalyzers. Depending on the affinity of antibodies and the detection technique, 
different assays may lead to the different screening results. 
Under approval of the Cantonal Ethic Committee Zurich (KEK-ZH-Nr. 2015-0483), we 
conducted a retrospective analysis to confirm our LSD screening results in urine samples. 
Results obtained with our currently employed screening test, namely with the kinetic 
interaction of microparticles in solution (KIMS) assay from Roche Diagnostics performed on 
Cobas Integra 800 analyzer, were compared with those from the cloned enzyme donor 
immunoassay (CEDIA) from Microgenics performed on Cobas c502 analyzer. Afterwards, 
results of immunoassays were confirmed by LC-MS analysis.  
In total, we analysed 50 urine samples as specified: KIMS screening on the fresh urine 
samples, followed by the replicated KIMS and CEDIA assays and LC-MS analysis on the 
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frozen urine samples (Table 1). The KIMS assay was replicated to ensure that preanalytical 
conditions are uniform for all three measurements.  
Our first rather unanticipated finding was a high number of the discrepant results between two 
KIMS assays: 14 urine samples were positive for LSD in the first screening but negative in 
the replicated assay and four urine samples were primarily negative but positive in the 
succeeding analysis (Table 1). Altogether, 36% of the results were discrepant (Figure 1A). 
Since there is no significant loss of LSD in the frozen state or after several freeze/thaw cycles 
(3, 4), this observed discrepancy cannot be explained only by different preanalytical 
conditions of the urine samples. For the KIMS immunoassay, triplicate measurement of the 
0.5 ng/ml LSD cut-off calibrator is used a reference to distinguish between positive and 
negative results. According to the test principle, the absorbance reduces proportionally to the 
increasing LSD concentration in the sample. Thus, the positive control containing 1 ng/ml 
LSD and the negative control containing 0.25 ng/ml LSD will produce signals below and 
above the cut-off calibrator, respectively. At higher absorbance values of the cut-off 
calibrator, negative controls may falsely fall below it, therefore being classified as positive. 
This problem was frequently observed in our laboratory and a new calibration to obtain lower 
absorbance values of the cut-off calibrator was required in order to pass the quality control. 
As suggested by our results, the same could apply to the urine samples. 
When compared with the LC-MS, KIMS assay showed rather poor total concordance of 
63.5% (Figure 1B). On the one hand, this might be attributed to poor analytical quality of the 
KIMS immunoassay as described above. On the other hand, it may be caused by interfering 
substances present in the urine. However, a general unknown screening with LC-MS did not 
identify any interfering substance. 
The CEDIA immunoassay allows both qualitative and semiquantitative applications. In the 
qualitative application only one 0.5 ng/ml cut-off calibrator is used as the reference. In our 
laboratory we apply semi-quantification and use one calibrator without LSD (negative 
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calibrator), and three calibrators containing LSD at the cut-off (0.5 ng/ml), with intermediate 
(1.5 ng/ml) and high (3.0 ng/ml) LSD concentration. The CEDIA assay showed overall 
satisfactory total concordance of 92.3% with LC-MS (Figure 1C). Two urine samples, which 
were positive for LSD in the CEDIA assay were negative in LC-MS, contained fentanyl. The 
cross-reactivity of fentanyl with the CEDIA assay is already known to cause false-positive 
findings (5). 
Furthermore, the comparison of the results from both immunoassays revealed an unacceptable 
high percentage (36.5%) of discrepant results (Figure 1D).  
It is worth to mention that two urine samples were positive in the confirmatory LC-MS 
analysis, but negative when analyzed with either immunoassay (Table 1). Except for very low 
creatinine concentration (1.0 and 1.9 mmol/l) indicating strong urine dilution, urine samples 
were not adulterated with glutaraldehyde, bleach, or pyridinium chlorochromate as shown by 
Intect 7 Urine Adulteration Test Strip. We speculate that discrepancies between 
immunoassays and LC-MS can be caused by other adulterant(s), lower sensitivity of 
immunoassays or urine dilution.  
To sum up, LSD screening using immunoassays have to be interpreted with the knowledge of 
the limitations of each assay. Moreover, as a rule, the results of drug screening in the urine 
using immunoassays should be considered as “presumptive positive” until confirmed by the 
MS-based technique.   
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Tabele 1  
Results of KIMS and CEDIA assays and confirmatory LC-MS in 52 analysed urine samples. 
*fresh urine samples, # urine samples after 1 freeze-thaw cycle.  
 
Nr. of urine 
samples 
first  
KIMS screening* 
replicated  
KIMS assay#  
CEDIA assay# LC-MS# 
2 positive positive positive detectable 
13 positive positive negative undetectable 
14 positive negative negative undetectable 
4 negative positive negative undetectable 
2 negative negative positive undetectable 
15 negative negative negative undetectable 
2 - negative negative detectable 
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Figure 1 
Concordance of obtained results between first KIMS screening and replicated KIMS assay 
(A), replicated KIMS assay and MS (B), CEDIA assay and MS (C), and replicated KIMS and 
CEDIA assays (D). 
 
 
 
 
 
 
